Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking an Ionis-partnered candidate that could offer dosing just once a year into pivotal trials on the strength of ...

Netherlands-based argenx has published positive topline results from its ADAPT SERON trial of its market-leading drug for generalised myasthenia gravis (gMG) Vyvgart (efgartigimod). Significantly, the ...

OpenAI has previously stated that it has adopted an 'opt-out' policy regarding IP – that means IP owners need to contact ...

In this edition, Sayantan writes about new emission reduction targets announced by countries, the growing fossil fuel footprint, and the true cost of room air conditioning in India.